Mammogen is a female-led precision health company dedicated to radically improving the detection, diagnosis and treatment of women's health-related diseases, and creating a diverse and thriving global community that encourages, empowers and uplifts women throughout the journey of survivorship, from end-to-never-end. Our flagship genTRU diagnostic program is a clinical-stage, patent-pending technology that measures changes in RNA expression patterns, found in both blood and saliva, to provide a highly accurate diagnosis of breast cancer consistently across all stages of disease. The genTRU-breast suite of diagnostics is intentionally designed to rule more of the right women into imaging and intervention much earlier and to rule more of the wrong women out of unnecessary procedures, and is positioned to unlock regular and reliable screening for hundreds of millions of women around the world.